Enliven Therapeutics, Inc. (ELVN)Healthcare | Biotechnology | Boulder, United States | NasdaqGS
46.41 USD
+46.41
(0.000%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:19 a.m. EDT
ELVN is in a choppy auction phase at its 5-year high; the high short-to-term rating reflects the recent surge's exhaustion, while the positive long-term signal relies on the underlying CML clinical data and strong balance sheet to support a recovery from current bearish technical levels. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.166543 |
| AutoTheta | 0.187272 |
| AutoETS | 0.195365 |
| AutoARIMA | 0.294929 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 46.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.067 |
| Excess Kurtosis | -0.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.087 |
| Market Cap | 2,775,336,960 |
| Forward P/E | -18.27 |
| Beta | 0.49 |
| Website | https://www.enliventherapeutics.com |
As of April 19, 2026, 12:19 a.m. EDT: Options data reveals mixed but distinct signals. The near-term (April 17) outlook is bearish, evidenced by aggressive put buying at 35-40 strikes with 100% OTM positioning among expirations, suggesting a hedge against a pullback from highs. However, longer-dated calls (June 18, Sept 18) show heavy Open Interest at 30-45 strikes with low ATM IV, indicating a 'long stock, quick option' strategy where speculators' bullish bias is priced in, yet implied volatility remains low elsewhere in the chain.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5826378 |
| Address1 | 6,200 Lookout Road |
| All Time High | 250.84 |
| All Time Low | 3.896 |
| Ask | 59.95 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,378,570 |
| Average Daily Volume3 Month | 1,159,563 |
| Average Volume | 1,159,563 |
| Average Volume10Days | 1,378,570 |
| Beta | 0.491 |
| Bid | 33.79 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 7.732 |
| City | Boulder |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 46.41 |
| Current Ratio | 28.662 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 48.15 |
| Day Low | 46.4 |
| Debt To Equity | 0.087 |
| Display Name | Enliven Therapeutics |
| Earnings Timestamp | 1,772,571,600 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -119,395,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -19.374 |
| Enterprise Value | 2,313,114,880 |
| Eps Current Year | -1.94 |
| Eps Forward | -2.54 |
| Eps Trailing Twelve Months | -1.83 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 33.3706 |
| Fifty Day Average Change | 13.039398 |
| Fifty Day Average Change Percent | 0.39074507 |
| Fifty Two Week Change Percent | 158.26378 |
| Fifty Two Week High | 48.53 |
| Fifty Two Week High Change | -2.119999 |
| Fifty Two Week High Change Percent | -0.043684296 |
| Fifty Two Week Low | 14.785 |
| Fifty Two Week Low Change | 31.625 |
| Fifty Two Week Low Change Percent | 2.1389923 |
| Fifty Two Week Range | 14.785 - 48.53 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,584,019,800,000 |
| Float Shares | 34,140,052 |
| Forward Eps | -2.54 |
| Forward P E | -18.271654 |
| Free Cashflow | -47,978,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08208 |
| Held Percent Institutions | 1.0670301 |
| Implied Shares Outstanding | 59,800,406 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado. |
| Long Name | Enliven Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,775,336,960 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_693128628 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -103,694,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,775,336,842 |
| Number Of Analyst Opinions | 7 |
| Open | 47.74 |
| Operating Cashflow | -70,301,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 720 647 8519 |
| Previous Close | 0.0 |
| Price Eps Current Year | -23.92268 |
| Price Hint | 2 |
| Price To Book | 6.002328 |
| Profit Margins | 0.0 |
| Quick Ratio | 27.923 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 46.41 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 48.15 |
| Regular Market Day Low | 46.4 |
| Regular Market Day Range | 46.4 - 48.15 |
| Regular Market Open | 47.74 |
| Regular Market Previous Close | 0.0 |
| Regular Market Price | 46.41 |
| Regular Market Time | 1,776,715,201 |
| Regular Market Volume | 483,690 |
| Return On Assets | -0.18652001 |
| Return On Equity | -0.26953 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 59,800,406 |
| Shares Percent Shares Out | 0.1012 |
| Shares Short | 6,053,456 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 7,979,674 |
| Short Name | Enliven Therapeutics, Inc. |
| Short Percent Of Float | 0.1436 |
| Short Ratio | 3.94 |
| Source Interval | 15 |
| State | CO |
| Symbol | ELVN |
| Target High Price | 60.0 |
| Target Low Price | 41.0 |
| Target Mean Price | 51.28571 |
| Target Median Price | 52.0 |
| Total Cash | 462,620,992 |
| Total Cash Per Share | 7.736 |
| Total Debt | 399,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -1.83 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.8991 |
| Two Hundred Day Average Change | 22.5109 |
| Two Hundred Day Average Change Percent | 0.9419142 |
| Type Disp | Equity |
| Volume | 483,690 |
| Website | https://www.enliventherapeutics.com |
| Zip | 80,301 |